USPTO serial 79377981
DERMATOPLEX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 19, 2025
- Examiner
- VENGURLEKAR, SAGAR S
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with DERMATOPLEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jefferson F. Scher
Jefferson F. Scher Carr & Ferrell LLP411 Borel Avenue, Suite 603San Mateo, CA 94402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical reagents for non-medical purposes; chemical reagents for scientific purposes; chemical solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with amplification, analysis or labeling of nucleic acid; enzyme preparations for industrial purposes to identify pathogens, infections, and infectious diseases; enzymes for scientific and research purposes; nucleic acids for scientific purposes; nucleic recombinant acids for scientific purposes; acids, namely, nucleic recombinant acids to identify pathogens, infections, and infectious diseases for scientific purposes; polymerase for scientific purposes; none of the foregoing for use in promoting plant growth or in enhancing the effectiveness of plant nutrients | ACTIVE | — |
| 005 | Reagents for medical and veterinary use; nucleic acid amplification reagents for medical use; nucleic acid sequencing programs for medical use to identify pathogens, infections, and infectious diseases; chemical preparations containing enzymes for medical purposes for treating infections and infectious diseases; chemical preparations containing enzymes for treating infections and infectious diseases for pharmaceutical, veterinary and medical purposes; enzyme preparations for pharmaceutical, veterinary and medical purposes; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to diagnose and identify pathogens, infections, and infectious diseases; diagnostic kits comprising diagnostic agents, preparations and substances for medical and veterinary use; diagnostic kits comprised of medical diagnostic reagents and assays for medical laboratory use in analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression, immune disorders, all for testing of bodily fluids for use in disease detection, namely, to diagnose and identify pathogens, infections, and infectious diseases; none of the foregoing for use in or as a medicated shampoo | ACTIVE | — |
| 010 | Surgical, medical and veterinary apparatus and instruments for diagnosis of disease, for detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy for treatment of infectious diseases, immunological diseases and autoimmune diseases; diagnostic testing apparatus and instruments for medical purposes, namely, for diagnosis of disease, for detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy for treatment of infectious diseases, immunological diseases and autoimmune diseases; medical diagnostic apparatus for testing for diagnosis of disease, for detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy for treatment of infectious diseases, immunological diseases and autoimmune diseases; point of care medical devices, namely, a device for testing for diagnosis of disease, for detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy for treatment of infectious diseases, immunological diseases and autoimmune diseases; diagnostic kits consisting primarily of probes, buffers and reagents for use in microbial testing; Anatomic pathology specimen collection kit comprising glass slides, centrifuge tubes, formalin jars, coplin jars, insert to hold slides and jars, absorbent cloth, and printed instructions, all for medical use | ACTIVE | — |
| 042 | Scientific research in the field of genetics; scientific research in the field of genetics and genetic engineering; research and development services in the field of chemistry; scientific research in the field of chemistry; research in the field of chemistry; research laboratory analysis services in the field of chemistry; development services in the field of medical diagnostic apparatuses; design of medical diagnostic apparatuses; research in the field of molecular sciences; data analysis for scientific research purposes in the field of scientific and medical experiments and tests; biological, bacteriological, chemical, biochemical, DNA, RNA, protein, polynucleic acid and molecular analysis and evaluation services, for scientific research purposes; DNA and RNA and polynucleic acid and protein sequencing, analysis and evaluation services for scientific research purposes; genome sequencing services and the analysis and evaluation of data resulting therefrom for scientific research purposes; providing reports relating to scientific and medical experiments, the results of scientific and medical experiments and tests, the analysis and evaluation of scientific and medical data, and data generated by scientific and medical experiments and tests; scientific and medical research and development services, for scientific research purposes; custom design and development of biochemical assays | ACTIVE | — |
| 044 | Medical services; human healthcare services in the field of diagnosis and identification of pathogens infections and infectious diseases; medical testing services relating to the diagnosis and treatment of disease; genetic testing for medical purposes; medical and health services in the field of DNA and genetic testing; medical diagnostic services in the nature of medical testing and analysis; molecular diagnostics testing for medical purposes; providing medical information in the field of genetic and treatment information for diseases and disorders for diagnostic and treatment purposes; analysis of medical diagnostic images and medical molecular tests for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SpeeDx Pty Ltd
- Other trademarks owned by SpeeDx Pty Ltd
- Other trademarks owned by SpeeDx Pty Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named DERMATOPLEX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 19, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 26, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 26, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 19, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 19, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 19, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 3, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 3, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 28, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 5, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 4, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 4, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 4, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 1, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 11, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 11, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 11, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 10, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 9, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 13, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 23, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 23, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 23, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 22, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 22, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 22, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 22, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 22, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 22, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 12, 2024 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Jul 7, 2024 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| May 13, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 12, 2024 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Apr 24, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 23, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 4, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 3, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 1, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 12, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 8, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 7, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |